Cited 11 times in
A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경래 | - |
dc.contributor.author | 김수정 | - |
dc.contributor.author | 김진석 | - |
dc.contributor.author | 민유홍 | - |
dc.contributor.author | 장종희 | - |
dc.contributor.author | 정준원 | - |
dc.date.accessioned | 2015-04-24T17:07:09Z | - |
dc.date.available | 2015-04-24T17:07:09Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104796 | - |
dc.description.abstract | The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated with intraventricular applications of rituximab to minimize neurotoxicity, 2 cycles of salvage chemotherapy with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy with autologous stem cell rescue. The high-dose chemotherapy consisted of bischloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) regimen. Partial remission was detected after intraventricular rituximab therapy and the patient has been in complete remission without evidence of neurotoxicity for 28 months after high-dose chemotherapy with autologous stem cell rescue. This case indicates a new appropriate treatment guideline in relapsed PCNSL patient after initial intensive chemo-radiotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 280~283 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antibodies, Monoclonal/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal, Murine-Derived | - |
dc.subject.MESH | Central Nervous System Neoplasms/drug therapy* | - |
dc.subject.MESH | Central Nervous System Neoplasms/therapy* | - |
dc.subject.MESH | Cytarabine/therapeutic use | - |
dc.subject.MESH | Etoposide/therapeutic use | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ifosfamide/therapeutic use | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/drug therapy* | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/therapy* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Rituximab | - |
dc.subject.MESH | Stem Cell Transplantation/methods* | - |
dc.title | A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학) | - |
dc.contributor.googleauthor | Sung Jin Hong | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Kyoung Min Kim | - |
dc.contributor.googleauthor | Soo Jeong Kim | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Seung Tae Lee | - |
dc.contributor.googleauthor | Yoo Hong Min | - |
dc.identifier.doi | 10.3349/ymj.2009.50.2.280 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00294 | - |
dc.contributor.localId | A00633 | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A01407 | - |
dc.contributor.localId | A03470 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 19430564 | - |
dc.subject.keyword | Primary central nervous system lymphoma | - |
dc.subject.keyword | high-dose chemotherapy with autologous stem cell rescue | - |
dc.subject.keyword | rituximab | - |
dc.subject.keyword | salvage therapy | - |
dc.contributor.alternativeName | Kim, Kyung Rae | - |
dc.contributor.alternativeName | Kim, Soo Jeong | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.alternativeName | Chang, Jong Hee | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Rae | - |
dc.contributor.affiliatedAuthor | Kim, Soo Jeong | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Chang, Jong Hee | - |
dc.contributor.affiliatedAuthor | Cheong, June-Won | - |
dc.citation.volume | 50 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 280 | - |
dc.citation.endPage | 283 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.50(2) : 280-283, 2009 | - |
dc.identifier.rimsid | 40796 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.